ABSI ABSCI CORP

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum.

Absci management is scheduled to participate in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

About Absci

is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our ™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (), X (Twitter) (), and .

Investor Contact

Alex Khan

VP, Finance & Investor Relations



Media Contact





EN
04/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABSCI CORP

 PRESS RELEASE

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. Absci management is scheduled to participate in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.ab...

 PRESS RELEASE

Absci to Participate in the TD Cowen 45th Annual Health Care Conferenc...

Absci to Participate in the TD Cowen 45th Annual Health Care Conference VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, MA. Absci management is scheduled to participate in a fireside chat on Monday, March 3rd at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: inve...

 PRESS RELEASE

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Con...

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY. Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relati...

 PRESS RELEASE

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generat...

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABSI), a data-first generative AI drug creation company, and , a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two...

 PRESS RELEASE

Absci and AMD Announce Collaboration and Strategic Investment to Accel...

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery $20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo ant...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch